EL Adds $14 a Share as Margins Expand 320 Basis Points and Sales Grow 3%

Estée Lauder (EL) closed Tuesday at $84.27 and traded $97.39 in the premarket, up 15.57%, before extending to gains of more than 17% after the Wednesday open — putting the stock near $98.60. That is a move of roughly $14.30 a share on a company that had been left for dead.

The trajectory through the morning was volatile. An early premarket reading had the stock up 6% at $89.65 before the conference call at 8:30 a.m. ET; by the open it was up 15% to 17%. The 52-week range runs $66.22 to $121.64, which places the current print roughly 19% below the high and 49% above the low.

The context makes the reaction legible. EL had dipped 10.9% over the trailing 52 weeks against a 16.5% gain in the S&P 500 and a 1.9% rise in the consumer staples ETF. Roughly $100 billion of market capitalization has evaporated since the post-pandemic high in early 2022, across three consecutive years of declining annual revenue.

That streak just ended. Fiscal 2026 delivered as-reported net sales growth of 5% for the full year and 6% in the fourth quarter, with organic growth of 3% for the year and 5% for the quarter — a fourth consecutive quarter of organic expansion.

Fourth-quarter adjusted EPS came in at $0.39 against a $0.32 consensus, a 21.9% beat. Revenue of $3.63 billion topped the $3.55 billion estimate by 2.25%. Adjusted operating income rose 95% to $267 million.

The guidance is what moved the stock. Fiscal 2027 adjusted EPS is guided to $3.10 to $3.35 against a $3.18 consensus, with adjusted operating margin raised to 12.7% to 13.5% from the preliminary 12.5% to 13.0% given in May.

A quarterly dividend of $0.35 per share on Class A and Class B stock was declared, payable September 15 to holders of record August 31.

The Margin Number Is the Whole Story

Strip the announcement to its components and the re-rating traces almost entirely to one line.

Fiscal 2026 operating margin expanded 320 basis points to 11.2%, with expansion of nearly 300 basis points or more in every single quarter of the year. Gross margin widened 150 basis points to 75.5%. Adjusted EPS rose 66% to $2.51 from $1.51. Operating cash flow increased 39% to $1.77 billion.

Those are the numbers of a company that fixed its cost structure. They are not the numbers of a company that fixed its demand problem.

Organic net sales grew 3% for the full year. The fiscal 2027 organic guidance of 3% to 5% was affirmed rather than raised — management explicitly used the word "affirming" while it "raised" the margin outlook. That asymmetry is the honest read on where confidence sits.

The margin raise itself is 20 basis points at the midpoint: from 12.75% to 13.1%. Management attributed it to strong fiscal 2026 results, continued leverage on non-consumer-facing expenses, and modest gross margin expansion. Every one of those drivers is a cost lever.

Run the arithmetic forward. Guided fiscal 2027 net sales of $15.50 billion to $15.80 billion against an adjusted operating margin of 12.7% to 13.5% produces operating income of roughly $1.97 billion to $2.13 billion, against approximately $1.74 billion implied by 11.2% on fiscal 2026 sales. The entire incremental operating profit comes about 60% from margin and 40% from volume.

That is a legitimate way to grow earnings and it has a known endpoint. Cost programs run out.

The Profit Recovery and Growth Plan has already delivered $1.2 billion in total gross benefits, matching the upper end of previously communicated targets. Actions are still expected to be substantially completed in fiscal 2027, with the vast majority of full run-rate benefits realized during that year.

Which means fiscal 2028 has to grow on revenue.

Fragrance and Skin Care Carried a Quarter Makeup Did Not

The category breakdown shows a business with two engines running and two stalling.

Skin care revenue rose 8.7% to $1.85 billion in the fourth quarter, the largest segment and the fastest grower in absolute dollars. Fragrance climbed 10% to $618 million — the strongest percentage growth in the portfolio. Makeup increased 2.9% to $1.01 billion. Hair care declined 0.7% to $140 million, the only category to shrink.

Jo Malone London and TOM FORD both joined the company's billion-dollar brand club during the year, which is the clearest evidence the luxury fragrance strategy is working.

Fragrance has been the consistent bright spot throughout the turnaround. Third-quarter commentary described double-digit fragrance growth as broad-based across most brands and all geographic regions, led by luxury names with strength in both the Americas and mainland China. The portfolio spans Le Labo, Frédéric Malle, KILIAN PARIS, TOM FORD and Jo Malone London — a genuinely premium stable in a category with pricing power.

Makeup is the problem and the opportunity simultaneously. At 2.9% growth it trailed estimates in the fourth quarter, and management is guiding to a return to full-year growth in fiscal 2027. That guidance is the single largest swing factor in the revenue outlook, because makeup at roughly $1 billion per quarter is close in size to skin care.

M·A·C, Too Faced, Smashbox and Bobbi Brown sit in the most competitive segment of beauty, facing e.l.f. Beauty on price and a fragmented indie field on newness. Recovering that category requires winning share rather than harvesting margin.

Hair care at $140 million is small enough that its 0.7% decline does not move the model, but it is the fourth consecutive category signal that the portfolio is uneven.

Geographically, sales increased across every region. The Americas returned to growth led by North America — the market that had been the deepest drag.

The Middle East Cost a Full Point of Growth

The one hard headwind in the quarter is quantified and it is larger than most reports acknowledged.

Business disruptions related to the Middle East conflict reduced consolidated sales growth by approximately 1 percentage point in the fourth quarter. The impact on Europe, the UK and emerging markets — the EUKEM segment — was roughly 2 percentage points.

That means organic growth of 5% would have been 6% absent the conflict, and the EUKEM region was carrying a materially heavier drag than the consolidated figure implies.

Travel retail is the transmission channel. Estée Lauder generates a substantial share of revenue through duty-free and airport channels, and the Strait of Hormuz disruption has reduced regional traffic while elevated fuel prices have compressed discretionary travel. Gulf-region travel retail is one of the highest-margin channels in the entire portfolio.

Management stated it does not currently expect the Middle East conflict to materially affect fiscal 2027 results, and will continue monitoring. That is an assumption embedded in the $15.50 billion to $15.80 billion revenue guide, and it is the assumption most likely to be wrong given that the 60-day U.S.-Iran memorandum expired Monday with no replacement and Brent sits at $92.

Tariffs delivered a partial offset. During the fourth quarter the company submitted claims for a portion of eligible tariffs paid and began receiving refunds, recording a $38 million benefit in cost of sales. That partially offset the full-year gross impact of incremental tariffs of $102 million.

Net tariff drag for fiscal 2026: $64 million. Whether further refunds arrive in fiscal 2027 is not in guidance, which mirrors how Target and Lowe's have treated the same IEEPA mechanism.

Travel retail is also the largest identified tailwind for the coming year. Management expects stronger first-half growth helped by earlier product launches, higher travel retail shipments reflecting improving retail trends, and a lower base of travel retail shipments in the first half of fiscal 2026 relative to the second.

That is a comparison benefit, not a demand recovery.

What $1.4 Billion of Restructuring Actually Bought

The cost program deserves examination because it is the engine of the entire earnings recovery.

Through June 30, 2026, the company has recognized total cumulative charges under the restructuring component of the Profit Recovery and Growth Plan of $1.4 billion, consisting primarily of employee-related costs. Fiscal 2026 alone accounted for $0.8 billion of that. Approvals for specific initiatives were concluded as of June 30, 2026, meaning the scoping phase is finished.

Total restructuring and other charges were guided at $1.5 billion to $1.7 billion as of the third quarter, against $1.2 billion of gross benefits already delivered.

That ratio is worth sitting with. The company has spent $1.4 billion in charges to capture $1.2 billion in gross annual benefits. The payback works if the benefits are durable and the charges stop — both of which management is signalling.

The operating model change underneath it is called One ELC, which de La Faverie describes as enabling the organization to move at speed and with discipline. Combined with Beauty Reimagined, the strategy is a full operational, leadership and cultural transformation — described internally as the biggest in company history.

The channel shift is the most tangible piece. Management has accelerated into higher-growth platforms including Amazon Premium, TikTok Shop and Douyin, driving roughly 10% online organic sales growth through the third quarter, while exiting select unproductive department-store doors.

Exiting department stores reduces revenue in the near term and improves margin — which is precisely what the fiscal 2026 numbers show. Organic growth of 3% with 320 basis points of margin expansion is a company trading volume for profitability.

That trade cannot repeat indefinitely. Door closures are finite, headcount reductions are finite, and the $1.2 billion of PRGP benefits is now largely banked.

Fiscal 2027 is the year the strategy has to convert into volume growth, and the affirmed 3% to 5% organic guide is the test.

The Valuation Argument Cuts Both Ways

At roughly $98.60 the stock trades at 30.6 times the fiscal 2027 adjusted EPS midpoint of $3.225. That is a full-recovery multiple.

The bull framing uses a different metric. The price-to-sales ratio sits at 2.07 against a historical median of 3.88 — the stock trades at roughly half its own long-run revenue multiple. Earnings-based valuation is described as not meaningful given ongoing GAAP losses, which is why the P/S comparison carries the argument.

The GF Score reads 74 out of 100, with valuation scoring a perfect 10 out of 10 and profitability at 7 out of 10 on a gross margin of 74.71% and an operating margin of 10.54%. Growth remains the identified weakness. One model puts the stock 13.0% undervalued against intrinsic value estimates, and separate analysis places it below fair value on the most-undervalued screen.

The bear framing focuses on what the multiple assumes. EV/EBITDA at 24.63 times is not a distressed valuation. Paying 30 times forward earnings for 3% to 5% organic revenue growth requires believing the margin path extends well beyond 13.5% — and management has not guided beyond fiscal 2027.

Compare that to where earnings sit historically. Fiscal 2025 adjusted EPS was $1.51. Fiscal 2026 delivered $2.51. Fiscal 2027 is guided to $3.10 to $3.35. That is a recovery from a depressed base, not growth from a normalized one, and the multiple is being applied to the recovery year rather than to the run rate.

Insider behavior is the uncomfortable data point. There have been no recent insider purchases and significant insider selling totaling over $1 billion in the past twelve months. Among nine premium institutional holders tracked, equal numbers have been adding and trimming.

More than a billion dollars of insider selling into a stock down 10.9% over twelve months is not a vote of confidence in the recovery, whatever the operating results say.

Analyst consensus had fiscal 2027 EPS at $3.18, up 32% from a projected fiscal 2026 figure of $2.41. The actual fiscal 2026 came in at $2.51, which means the base was already better than modeled.

A Fourth Straight Quarter of Growth Is Not a Trend Yet

The strongest argument for the move is consistency, and it is worth stating precisely.

Fiscal 2026 delivered organic sales growth in all four quarters, with organic growth accelerating to 5% in the fourth. Margin expansion occurred in every quarter of the year, at nearly 300 basis points or more each time. Full-year EPS rose 66%. The trailing four-quarter average earnings surprise runs 39.1%.

That is not a single good print. It is a pattern, and patterns are what justify multiple expansion.

The quarterly progression through fiscal 2026 shows the acceleration. Second-quarter net sales reached $4.229 billion, up 6% from $4.004 billion. Third quarter delivered 2% organic growth with diluted EPS up 40% to $0.91, driven by 140 basis points of gross margin improvement to 76.4% and 360 basis points of operating margin expansion to 15%. Fourth quarter closed with 5% organic and the $0.39 adjusted figure.

The company entered fiscal 2026 having raised guidance twice — in February after a strong first half, and again in the third quarter alongside the preliminary fiscal 2027 view of 3% to 5% organic and a 12.5% to 13.0% operating margin.

Every one of those raises has now been met or exceeded. Fiscal 2026 came in ahead of the expectations management set at the start of the year, with organic sales rising 3% against an initial target of roughly 3% and operating margin of 11.2% against a 10.7% to 11.0% guide.

That execution record is why the stock added 17% rather than 5%.

The counterweight is what the four quarters are being compared against. Fiscal 2025 was the third consecutive year of revenue decline in a period that destroyed roughly $100 billion of market value. Growing 3% off that base is a low bar, and the comparisons get harder from here.

Fiscal 2027 first-half strength is explicitly attributed to easier comparisons and shipment timing rather than underlying demand acceleration.

The China and Travel Retail Question Nobody Answered

The two variables that broke Estée Lauder in the first place received limited disclosure, and that omission matters.

Travel retail was the channel that drove the collapse from the early-2022 peak. Chinese duty-free demand, Hainan volumes and airport traffic across Asia were the growth engine that reversed. The recovery of that channel is the single largest determinant of whether 3% organic becomes 5%.

Management's fiscal 2027 guidance explicitly cites an increase in travel retail shipments reflecting retail trend improvements entering the year, plus a lower base of travel retail shipments in the first half of fiscal 2026. Jefferies noted travel retail trends are improving heading into the new fiscal year.

Improving from a depressed base is different from recovered. Neither the release nor the initial commentary quantified travel retail as a percentage of sales or its growth rate in the fourth quarter.

Mainland China appeared only obliquely. Third-quarter commentary cited fragrance strength in both the Americas and mainland China as a driver of double-digit growth in that category. The fourth-quarter release noted sales growth across every geographic region without breaking out China specifically.

The Middle East disruption reduced EUKEM growth by 2 percentage points, which is the only regional headwind quantified.

The channel shift toward Amazon Premium, TikTok Shop and Douyin is the strategic answer to a weakened travel retail and department-store base. Roughly 10% online organic growth through the third quarter is real progress, and Douyin specifically is the China-facing piece of that strategy.

Whether digital volume carries the margin that duty-free did is the unanswered question. Travel retail historically ran at premium margins because it bypassed retailer economics entirely. Amazon and TikTok Shop do not.

The company sells in approximately 150 countries under more than twenty brands including La Mer, Clinique, M·A·C, Origins, Aveda, Dr.Jart+ and the DECIEM family with The Ordinary.

Where This Sits Against the Beauty Complex

The peer comparison sharpens what the market is actually paying for.

L'Oréal remains the structural benchmark, having grown through the period that broke Estée Lauder — a function of broader category exposure, stronger China execution and less travel-retail dependence. Estée Lauder's recovery is measured against L'Oréal's consistency rather than against its own history.

At the mass end, e.l.f. Beauty has taken share in makeup through price and social-first marketing, which is precisely the pressure keeping EL's makeup category at 2.9% growth. Ulta Beauty provides the U.S. distribution read-through, and Coty offers the closest comparison as another legacy portfolio working through a turnaround.

Kenvue sits in the adjacent consumer health space with a similar profile: large brands, margin recovery story, depressed multiple.

The distinguishing feature of the Estée Lauder case is that its problem was never brand equity. La Mer, Jo Malone London, TOM FORD and Le Labo retain pricing power — TOM FORD and Jo Malone joining the billion-dollar club this year proves it. The problem was channel concentration and cost structure, and both are being addressed.

That is a materially better setup than a company facing brand erosion, and it is the reason the market is willing to pay 30 times forward earnings for a 3% to 5% grower.

The consumer staples backdrop has been weak. The sector ETF gained just 1.9% over the past 52 weeks against 16.5% for the S&P 500, meaning EL's 10.9% decline came inside a group that was already lagging badly.

A 17% single-session move in a $30-plus billion staples name is unusual and reflects how much short positioning and skepticism had accumulated. The Zacks Rank sat at 3 with an Earnings ESP of +6.32% heading in — a model predicting a beat against a market that had stopped believing.

The Cash Flow Number Deserves More Attention

Operating cash flow rose 39% to $1.77 billion in fiscal 2026, and that figure carries more information than the EPS line.

Cash flow growth of 39% against adjusted EPS growth of 66% shows earnings quality improving from a very low base without fully converting. Restructuring charges of $0.8 billion recognized in fiscal 2026 are largely cash costs, which suppresses the reported operating cash figure relative to the underlying run rate.

The implication is that fiscal 2027 cash generation should improve disproportionately as restructuring winds down. Charges are guided at $1.5 billion to $1.7 billion in total against $1.4 billion already recognized, meaning $100 million to $300 million remains — versus $800 million absorbed this year.

That swing alone is worth roughly $500 million to $700 million of incremental cash flow, before any operating improvement.

The dividend is covered and stable at $0.35 quarterly. On approximately 360 million shares that is roughly $500 million annually, comfortably funded from $1.77 billion of operating cash even in the restructuring year.

Balance sheet flexibility matters here because the company has been carrying elevated leverage through the downturn while maintaining the payout. Restoring cash generation is what allows the dividend to survive and eventually grow.

Capital allocation priorities have not been restated alongside these results. With PRGP substantially complete in fiscal 2027 and cash flow recovering, the question of buybacks versus reinvestment versus debt reduction becomes live — and at a stock 19% below its 52-week high, repurchases would be accretive.

Nothing in the release addressed it.

The trailing gross margin of 74.71% and operating margin of 10.54% are the figures the market is being asked to extrapolate toward a 12.7% to 13.5% guided operating margin. That is a 220 to 300 basis point improvement, and it is entirely dependent on the PRGP benefits holding as sales grow.

What Would Break the Thesis

The bear case has three specific failure points and each is testable within twelve months.

The first is makeup. Guidance calls for a return to full-year growth in fiscal 2027 after 2.9% in the fourth quarter and a weak year. Makeup at roughly $4 billion annualized is close to a quarter of the business, and it faces the most competitive pressure. If makeup stays flat, the 3% to 5% organic guide falls to the bottom of the range and the margin story has to carry everything.

The second is the Middle East. Management explicitly assumes no material impact on fiscal 2027, after the conflict cost a full point of consolidated growth and two points of EUKEM growth in the fourth quarter. The 60-day memorandum expired Monday with nothing replacing it, Brent sits at $92, and eight vessel attacks have been logged in the Strait this month. That assumption is the most exposed in the entire guide.

The third is the durability of the cost program. PRGP has delivered $1.2 billion of gross benefits at the top end of targets, with the vast majority of full run-rate benefits still expected during fiscal 2027. Cost programs that hit the top of their range typically do so by pulling forward savings, and the fiscal 2028 base becomes harder as a result.

The valuation compounds all three. At 30 times the fiscal 2027 midpoint, the stock has removed most of the margin of safety that existed at $84.27 and all of it that existed at the $66.22 low.

The offsetting consideration is that consensus was $3.18 and guidance midpoint is $3.225 — a beat of just 1.4%. The stock rose 17% on a 1.4% guidance beat and a 21.9% quarterly EPS beat, which means the move is about narrative confirmation rather than numbers.

Narrative-driven re-ratings retrace when the next quarter is merely in line.

The first fiscal 2027 quarterly report is the immediate test, with the company having guided to stronger first-half growth on earlier launches and easier comparisons.

Levels, Scenarios and the Verdict

The technical picture after a 17% gap is defined by the gap itself and by the 52-week structure above it.

Support starts at $97.39, the premarket print and the level where two-way trade developed. Beneath that, $89.65 marks the early premarket reading and the midpoint of the gap. The gap origin at $84.27 is the full retracement level and would represent giving back the entire move.

Resistance is thinner because the stock has not traded here in months. The 52-week high at $121.64 is the ultimate marker, 23% above current levels. Between $98.60 and $121.64 the chart is essentially empty, which cuts both ways: no overhead supply to absorb buying, and no structure to catch a reversal.

The scenario map runs on guidance execution. Delivering the top of the fiscal 2027 range — $3.35 adjusted EPS and 13.5% operating margin — at a 33 times multiple produces $110. Hitting the midpoint of $3.225 at 30 times holds current levels. Landing at the bottom at $3.10 with makeup still flat and Middle East disruption persisting reprices toward $85 on a 27 times multiple.

The valuation floor sits at the P/S argument. At 2.07 times sales against a 3.88 historical median, the stock has room even after a 17% day — but closing that gap requires revenue growth reaccelerating well beyond 5%, which nothing in guidance contemplates.

The verdict: this is a genuine turnaround and a margin story wearing a growth label. Fiscal 2026 ended three straight years of revenue decline with organic growth of 3%, gross margin up 150 basis points to 75.5%, operating margin up 320 basis points to 11.2%, and adjusted EPS up 66% to $2.51. The execution has been real and consistent across four quarters.

But the fiscal 2027 raise was to margin, not to sales. Organic growth of 3% to 5% was affirmed, not lifted. Fragrance at +10% and skin care at +8.7% carried a quarter where makeup grew 2.9% and hair care fell 0.7%. The PRGP has already banked $1.2 billion at the top of its range with $1.4 billion of charges spent to get there, and the benefits are substantially complete in fiscal 2027.

At roughly $98.60 the stock trades at 30.6 times the guided midpoint with over $1 billion of insider selling behind it in twelve months. Base case: consolidation between $89.65 and $110 into the first fiscal 2027 report. The next leg requires makeup to grow and travel retail to recover — neither of which was quantified today.

That's TradingNEWS